SCHEMBL3010626

SCHEMBL3010626

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(Cc4cc(C)cc(C)c4)cs3)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 4/20 0.45
KMT2A Q03164 1/20 0.39
MAPT P10636 3/20 0.39
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
THRB P10828 1/20 0.38
GAA P10253 2/20 0.38
RECQL P46063 1/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 2/20 0.37
REV1 Q9UBZ9 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004114 0.93 ALDH1A1 (0.43) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3015260 0.93 ALDH1A1 (0.39) ALDH1A1HSD17B10HPGDL3MBTL1MAPT
SCHEMBL15671708 0.93 ALDH1A1 (0.44) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3009529 0.92 ALDH1A1 (0.41) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL2997817 0.92 ALDH1A1 (0.47) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3017542 0.91 ALDH1A1 (0.43) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3006527 0.91 ALDH1A1 (0.43) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3013857 0.90 ALDH1A1 (0.42) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3000603 0.90 GAA (0.39) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A
SCHEMBL3016285 0.90 MAPK1 (0.39) ALDH1A1HSD17B10HPGDL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885HSD17B10 2553/4885HPGD 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.